BlackRock’s Orexigen Therapeutics, Inc. OREX Stock Holding History

BlackRock’s Portfolio OREX Stock Details OREX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-225,287	Closed	-$290K	–	5131
2017 Q4	$290K	Buy	225,287 +908	+0.4%	+$1.48K	﹤0.01%	4134
2017 Q3	$476K	Sell	224,379 -525	-0.2%	-$1.28K	﹤0.01%	4069
2017 Q2	$653K	Buy	224,904 +6,111	+3%	+$18.3K	﹤0.01%	3951
2017 Q1	$752K	Buy	+218,793	New	+$864K	﹤0.01%	3867
2016 Q2	–	Sell	-397	Closed	-$2K	–	3956
2016 Q1	$2K	Buy	397 +143	+56%	+$1.86K	﹤0.01%	3498
2015 Q4	$4K	Hold	254	–	–	﹤0.01%	3243
2015 Q3	$5K	Hold	254	–	–	﹤0.01%	3069
2015 Q2	$13K	Sell	254 -21	-8%	-$1.25K	﹤0.01%	2658
2015 Q1	$22K	Hold	275	–	–	﹤0.01%	2336
2014 Q4	$17K	Hold	275	–	–	﹤0.01%	2469
2014 Q3	$12K	Hold	275	–	–	﹤0.01%	2649
2014 Q2	$17K	Sell	275 -2	-0.7%	-$116	﹤0.01%	2495
2014 Q1	$18K	Buy	277 +23	+9%	+$1.56K	﹤0.01%	2430
2013 Q4	$14K	Hold	254	–	–	﹤0.01%	2554
2013 Q3	$16K	Hold	254	–	–	﹤0.01%	2399
2013 Q2	$15K	Buy	+254	New	+$15.6K	﹤0.01%	2466

Other funds holding OREX

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

OWIM

Old West Investment Management Los Angeles, California $923M AUM 112.31% 1-Year Est. Return

Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

BlackRock's OREX Position: Q1 2018 in Review

BlackRock sold out of Orexigen Therapeutics, Inc. (OREX) in Q1 2018, closing a stake of 225,287 shares — an estimated $290K sold.

BlackRock first reported a position in OREX in Q2 2013 and held it in 16 quarters. The position peaked at $752K in Q1 2017. 27 funds tracked by Wall St. Rank hold OREX as of Q1 2018.

BlackRock reported no remaining Orexigen Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
BlackRock sold 225,287 Orexigen Therapeutics, Inc. shares in Q1 2018, an estimated $290K.
BlackRock first reported a position in Orexigen Therapeutics, Inc. in Q2 2013 and held it in 16 quarters.
BlackRock's Orexigen Therapeutics, Inc. position peaked at $752K in Q1 2017.
27 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q1 2018.

Based on BlackRock's 13F filing for Q1 2018, filed 9 May 2018.